BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 18671852)

  • 1. Integrative analysis of RUNX1 downstream pathways and target genes.
    Michaud J; Simpson KM; Escher R; Buchet-Poyau K; Beissbarth T; Carmichael C; Ritchie ME; Schütz F; Cannon P; Liu M; Shen X; Ito Y; Raskind WH; Horwitz MS; Osato M; Turner DR; Speed TP; Kavallaris M; Smyth GK; Scott HS
    BMC Genomics; 2008 Jul; 9():363. PubMed ID: 18671852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
    Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
    Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Key Genes and Pathways Associated with RUNX1 Mutations in Acute Myeloid Leukemia Using Bioinformatics Analysis.
    Zhu F; Huang R; Li J; Liao X; Huang Y; Lai Y
    Med Sci Monit; 2018 Oct; 24():7100-7108. PubMed ID: 30289875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
    Hyde RK; Liu P; Friedman AD
    Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
    Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid neoplasms with germ line RUNX1 mutation.
    Hayashi Y; Harada Y; Huang G; Harada H
    Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
    Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Familial platelet disorder with predisposition to myeloid leukemia (FPD/AML): a case report and literature review].
    Zhang RR; Chen XJ; Ren YY; Yang WY; Zhu XF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):308-312. PubMed ID: 33979975
    [No Abstract]   [Full Text] [Related]  

  • 10. [A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree].
    Guan J; Wang LL; Wang CY; Zhu XM; Shuai HZ; Yi X; Zou L; Yu D; Cheng H
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):393-400. PubMed ID: 37032134
    [No Abstract]   [Full Text] [Related]  

  • 11. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
    Preudhomme C; Renneville A; Bourdon V; Philippe N; Roche-Lestienne C; Boissel N; Dhedin N; André JM; Cornillet-Lefebvre P; Baruchel A; Mozziconacci MJ; Sobol H
    Blood; 2009 May; 113(22):5583-7. PubMed ID: 19357396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
    Metzeler KH; Bloomfield CD
    Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
    Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
    Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.
    Latger-Cannard V; Philippe C; Bouquet A; Baccini V; Alessi MC; Ankri A; Bauters A; Bayart S; Cornillet-Lefebvre P; Daliphard S; Mozziconacci MJ; Renneville A; Ballerini P; Leverger G; Sobol H; Jonveaux P; Preudhomme C; Nurden P; Lecompte T; Favier R
    Orphanet J Rare Dis; 2016 Apr; 11():49. PubMed ID: 27112265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets.
    Glembotsky AC; Bluteau D; Espasandin YR; Goette NP; Marta RF; Marin Oyarzun CP; Korin L; Lev PR; Laguens RP; Molinas FC; Raslova H; Heller PG
    J Thromb Haemost; 2014 May; 12(5):761-72. PubMed ID: 24606315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Familial leukemia due to germline RUNX1 mutations: lessons learned from two decades of research and unsolved problems].
    Osato M; Nambu A
    Rinsho Ketsueki; 2020; 61(6):687-696. PubMed ID: 32624544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B.
    Chen Y; Chen S; Lu J; Yuan D; He L; Qin P; Tan H; Xu L
    Medicine (Baltimore); 2021 May; 100(18):e25807. PubMed ID: 33950983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
    Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
    Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
    Engel ME; Hiebert SW
    Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.